Gates Package — page 813

From: "Collins, Francis (NIH/NHGRI) [E]" HE ont. cov> To: "Gibbons, Gary (NIH/NHLBD [E]" HE 211i. gov>, "Panepinto, Julie (NIH/NHLBI) [E]" Hee eee omar "Dieffenbach, Carl (NIH/NIAID) [E]" iaid.nih.gov>, "Fauci, Anthony (NIH/NIAID) [E]" niaid.nih.gov> Ce: "Tabak, Lawrence (NIH/OD) [E]" HE 1b. 20v>, "Schwetz, Tara (NIH/OD) CE)" i. ov Subject: RE: Seeing Bill Gates tomorrow Date: Tue, 27 Sep 2022 06:58:10 -0400 Importance: Normal Attachments: Sickle_mouse_gene_editing.pdf PS. I did see the recent JCI Insight paper that shows impressive results for in vivo gene editing of the fetal globin promoter in the mouse model of sickle cell disease. Cites support from NHLBI, NHGRI, and NIGMS. Also support from BMGF. Cool stuff. See attached. From: Collins, Francis (NIH/NHGRI) [E] Sent: Tuesday, September 27, 2022 6:48 AM To: Gibbons, Gary (NIH/NHLBI) [E] Dieffenbach, Carl (NIH/NIAID) [E] Cc: Tabak, Lawrence (NIH/OD) [E] Subject: Seeing Bill Gates tomorrow nih.gov>; niaid.nih.gov> nih.gov> nih.gov>; Panepinto, Julie (NIH/NHLBI) [E] niaid.nih.gov>; Fauci, Anthony (NIH/NIAID) [E] nih.gov>; Schwetz, Tara (NIH/OD) [E] Hi all, Bill Gates is at the White House tomorrow and asked to see me at 9 AM. Among the topics we will likely discuss is the HIV-SCD joint NIH-BMGF effort to develop cures that will be applicable in low income settings. Are there any new developments since the Sunnylands meeting back in May? Bill will likely ask about the future of this partnership. Thanks, Francis